Who owns Zymeworks Inc. (ZYME)? Elite investor 13F holders

3 tracked elite investors reported holding Zymeworks Inc as of 2026-09-30, including Rubric Capital, D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Rubric CapitalZymeworks Inc - USSHARE2026-06-302026-08-14 00:00:00182980000.00 USD7000000.000000SharesholdOriginal filing
D.E. ShawZymeworks Inc - USSHARE2026-06-302026-08-14 00:00:003785255.00 USD144807.000000SharesreduceOriginal filing
Tudor InvestmentZymeworks Inc - USSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing
Renaissance Technologies LLCZymeworks Inc - USSHARE2026-09-302026-11-12 00:00:00709932.00 USD26800.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown